Esta tradução está a ser preparada. Entretanto, mostramos temporariamente a versão original em inglês.
Negócios · 08/08/20031 min de leitura
Agency Information Collection Activities; Announcement of OMB Approval; Applications for FDA Approval to Market a New Drug: Patent Submission and Listing Requirements and Application of 30-Month Stays on Approval of Abbreviated New Drug Applications Certifying That a Patent Claiming a Drug Is Invalid or Will Not Be Infringed
Tradução automática local · Idioma original da fonte
Resumo
The Food and Drug Administration (FDA) is announcing that a collection of information entitled "Applications for FDA Approval to Market a New Drug: Patent Submission and Listing Requirements and Application of 30-Month Stays on Approval of Abbreviated New Drug Applications Certifying That a Patent Claiming a Drug Is Invalid or Will Not Be Infringed" has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.
Idioma original da fonte: Federal Register — Food and Drug AdministrationAbrir o comunicado original →